A5091703668- SARS-CoV-2 and COVID-19 Research
- SARS-CoV-2 detection and testing
- COVID-19 Clinical Research Studies
- Immune Response and Inflammation
- Respiratory viral infections research
- Immunotherapy and Immune Responses
- Pediatric health and respiratory diseases
- Animal Virus Infections Studies
- Influenza Virus Research Studies
- Viral gastroenteritis research and epidemiology
- Transgenic Plants and Applications
Janssen (Netherlands)
2022-2024
Johnson & Johnson (Netherlands)
2024
Abstract The spike protein (S) of SARS-CoV-2 induces neutralizing antibodies and is the key component current COVID-19 vaccines. most efficacious vaccines are genetically-encoded spikes with a double proline substitution in hinge region to stabilize S prefusion conformation (S-2P). A subunit vaccine can be valuable addition mRNA viral vector-based but requires high stability spike. In addition, further stabilization might improve immunogenicity. To test this, five proteins were designed...
Abstract Since the original outbreak of SARS-CoV-2 virus, several rapidly spreading variants concern (VOC) have emerged. Here, we show that a single dose Ad26.COV2.S (based on Wuhan-Hu-1 spike variant) protects against Gamma and Delta in naive hamsters, supporting observed maintained vaccine efficacy humans these VOC. Adapted spike-based booster vaccines targeting Omicron now been authorized absence human data. We evaluated immunogenicity Ad26.COV2.S.529 (encoding stabilized BA.1 spike) mice...
Abstract Seasonal influenza vaccines must be updated annually and suboptimally protect against strains mismatched to the selected vaccine strains. We previously developed a subunit antigen consisting of stabilized trimeric A group 1 hemagglutinin (H1) stem protein that elicits broadly neutralizing antibodies. Here, we further optimized stability manufacturability H1 (H1 v2, also known as INFLUENZA G1 mHA) characterized its formulation potency with different adjuvants in vitro animal models....
Human metapneumovirus (HMPV) is a significant respiratory pathogen, particularly in vulnerable populations. No vaccine for the prevention of HMPV currently licensed, although several subunit vaccines are development. Saponin-based adjuvant systems (AS), including QS-21, have transformed field by dramatically increasing their potency and efficacy, leading to development licensed vaccines. However, naturally sourced tree bark-extracted QS-21 faces supply manufacturing challenges, hindering...
Abstract The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant sparked concern due to its fast spread and the unprecedented number of mutations in spike protein that enables it partially evade spike-based COVID-19 vaccine-induced humoral immunity. In anticipation a potential need for an vaccine, we generated Ad26 vector encoding (BA.1) (Ad26.COV2.S.529). Ad26.COV2.S.529 encodes prefusion stabilized protein, similar current vaccine Ad26.COV2.S Wuhan-Hu-1 protein. We...